<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Naguib S</submitter><funding>NIA NIH HHS</funding><pubmed_abstract>The Christchurch mutation (R136S) on the &lt;i>APOE3&lt;/i> (&lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> ) gene is associated with attenuation of tau load and cognitive decline despite the presence of a causal &lt;i>PSEN1&lt;/i> mutation and high levels of amyloid beta pathology in the carrier&lt;sup>1&lt;/sup>. However, the specific molecular mechanisms enabling the &lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> mutation to mitigate tau-induced neurodegeneration remain unclear. Here, we replaced mouse &lt;i>ApoE&lt;/i> with wild-type human &lt;i>E3&lt;/i> or &lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> on a tauopathy background. The &lt;i>R136S&lt;/i> mutation markedly decreased tau load and protected against tau-induced synaptic loss, myelin loss, and reduction in theta and gamma powers. Additionally, the &lt;i>R136S&lt;/i> mutation reduced interferon response to tau </pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2024.04.25.591140</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11071490</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&amp;lt;i&amp;gt;APOE3&amp;lt;/i&amp;gt;-&amp;lt;i&amp;gt;R136S&amp;lt;/i&amp;gt; mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition.</pubmed_title><pmcid>PMC11071490</pmcid><funding_grant_id>R01 AG072758</funding_grant_id><funding_grant_id>F32 AG085960</funding_grant_id><funding_grant_id>RF1 AG079557</funding_grant_id><funding_grant_id>R01 AG074541</funding_grant_id><funding_grant_id>R01 AG079291</funding_grant_id><pubmed_authors>Lopez-Lee C</pubmed_authors><pubmed_authors>Norinsky R</pubmed_authors><pubmed_authors>Gong S</pubmed_authors><pubmed_authors>Torres ER</pubmed_authors><pubmed_authors>Norman K</pubmed_authors><pubmed_authors>Wu Z</pubmed_authors><pubmed_authors>Zhao M</pubmed_authors><pubmed_authors>Bhagwat M</pubmed_authors><pubmed_authors>Patel T</pubmed_authors><pubmed_authors>Mok SA</pubmed_authors><pubmed_authors>Fan L</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Wong MY</pubmed_authors><pubmed_authors>Ambaw YA</pubmed_authors><pubmed_authors>Lee SI</pubmed_authors><pubmed_authors>Castaneda R</pubmed_authors><pubmed_authors>Zhu D</pubmed_authors><pubmed_authors>Farese RV</pubmed_authors><pubmed_authors>Naguib S</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Sinha S</pubmed_authors><pubmed_authors>Ye P</pubmed_authors><pubmed_authors>Gan L</pubmed_authors><pubmed_authors>Luo W</pubmed_authors><pubmed_authors>Walther TC</pubmed_authors></additional><is_claimable>false</is_claimable><name>&amp;lt;i&amp;gt;APOE3&amp;lt;/i&amp;gt;-&amp;lt;i&amp;gt;R136S&amp;lt;/i&amp;gt; mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition.</name><description>The Christchurch mutation (R136S) on the &lt;i>APOE3&lt;/i> (&lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> ) gene is associated with attenuation of tau load and cognitive decline despite the presence of a causal &lt;i>PSEN1&lt;/i> mutation and high levels of amyloid beta pathology in the carrier&lt;sup>1&lt;/sup>. However, the specific molecular mechanisms enabling the &lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> mutation to mitigate tau-induced neurodegeneration remain unclear. Here, we replaced mouse &lt;i>ApoE&lt;/i> with wild-type human &lt;i>E3&lt;/i> or &lt;i>E3&lt;/i> &lt;sup>&lt;i>S/S&lt;/i>&lt;/sup> on a tauopathy background. The &lt;i>R136S&lt;/i> mutation markedly decreased tau load and protected against tau-induced synaptic loss, myelin loss, and reduction in theta and gamma powers. Additionally, the &lt;i>R136S&lt;/i> mutation reduced interferon response to tau </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2026-05-30T03:11:36.532Z</modification><creation>2026-05-30T03:06:40.819Z</creation></dates><accession>S-EPMC11071490</accession><cross_references><pubmed>38712164</pubmed><doi>10.1101/2024.04.25.591140</doi></cross_references></HashMap>